Terbium-161: new radionuclide for targeted cancer therapy hits the clinic (IMAGE)
Caption
The radiopharmaceutical consists of a radioactive molecule – in this case terbium-161 linked to a ligand. This ligand recognises proteins on the tumour cell, allowing highly targeted cancer treatment. Now, it is being tested in patients for prostate cancer and neuroendocrine tumours.
Credit
Image: Paul Scherrer Institute / Ella Maru Studios
Usage Restrictions
PSI provides image and/or video material free of charge for media coverage of the content of the above text. Use of this material for other purposes is not permitted. This also includes the transfer of the image and video material into databases as well as sale by third parties.
License
Original content